Educational guide
3rd Peptide-Based Therapeutics Summit 2026
Peptide therapies are rapidly becoming a disruptive modality, with Unnatural Products scoring a $1.7B deal with Novartis , Vivtex 's $2.1B partnership with Novo Nordisk , and Pinnacle Medicines raising $89M for oral peptides , these investments signal a shift
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Peptide therapies are rapidly becoming a disruptive modality, with Unnatural Products scoring a $1.7B deal with Novartis, Vivtex's $2.1B partnership with Novo Nordisk, and Pinnacle Medicines raising $89M for oral peptides, these investments signal a shift in priority for peptide discovery and delivery towards improving chemistry, formulation and ultimately clinical efficacy.
To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returned to Boston as the industry’s only dedicated platform, turbocharging the next generation of peptide discoveries and advancing development efforts toward life-saving treatments.
Bringing together industry leaders including Unnatural Products, Vilya Therapeutics, Parabilis Medicines, Circle Pharma, Vivtex, Pinnacle Medicines, Eli Lilly, Protagonist Therapeutics, Merck & Co, Johnson & Johnson, Novo Nordisk, Endevica, Novartis, Peptinovo Biopharma, MBX Biosciences, 20N Bio and many more, this is your premium forum to explore the power of peptide computation, optimizing analytics, improving oral bioavailability and translating the pharmacology with clinical safety.
The event welcomed over 140 stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.